This enzyme is known as glycerol 3-phosphate phosphatase ( G3PP ). We just discovered its presence in mammalian cells. It plays a key role in eliminating the effects of excess sugar, the researchers explain the basis of this discovery, whose work is directed by Marc Prentki Madiraju Murthy and Research Center Hospital of the University of Montreal (CRCHUM). This advance is was published Monday in the Proceedings of the American Academy of Sciences (PNAS).

Obesity, diabetes and cardiovascular diseases

When glucose is abnormally high in the body, the glycerol 3-phosphate derived from glucose reached excessive levels in cells which can cause tissue damage. “ We found that the G3PP can degrade much of the glycerol 3-phosphate excess and away from the cell, so that the pancreatic beta cells producing insulin and the various bodies are protected from the effects toxic high levels of glucose “says Marc Prentki, professor at the University of Montreal.

glucose and fatty acids are the main nutrients in mammalian cells. Their use in cells regulates many physiological processes such as the secretion of insulin by the pancreas, liver glucose, lipid storage in adipose tissue and nutrient metabolism for producing energy. Dysregulation of these processes causes obesity, adult-onset diabetes (type 2) and cardiovascular diseases. Insulin is a key hormone produced by cells of the pancreas to regulate the utilization of glucose and lipids. If these cells are exposed to too much glucose and fatty acids, the same nutrients become toxic and adversely affect, causing their dysfunction and diabetes.

New therapeutic target

G3PP The enzyme is therefore essential for the functioning of metabolism being necessary both for energy production and training lipids, the researchers said. The results of this work provide a new therapeutic target against obesity, diabetes and metabolic syndrome.

For that scientists are trying to find “ small molecules that activate enzyme G3PP “which if successful and after successful tests on animals, would constitute an entirely new class of treatment against diabetes and obesity.

(With AFP)